CURRICULUM VITAE ANDREW C.

ROSENTHAL (LOWY)
JUNE 2008
PERSONAL DETAILS Name: Address: Andrew Curt Rosenthal 26/4 Mitchell Road Darling Point NSW 2027 (61 2) 9362 1966 (home) (61 414) 908 809 (mobile) (61 2) 9362 1900 andrew@acrc.com.au 14 November 1966 Sydney, Australia Single English French (basic conversation)

Telephone: Facsimile: Email: Date of birth: Place of birth: Marital Status: Languages spoken:

Medical Registration Number: MPO: 265930

ACADEMIC HISTORY 1972–1984: 1985–87: 1988: 1989–90: Sydney Grammar School Higher School Certificate, 1984 University of New South Wales: medical student (Years 1-3) Department of Neurology, Prince Henry Hospital: Bachelor of Medical Science (research/thesis) Medical student (Years 4-5)

Academic qualifications: 1989: 1991: 1998: 2000: 2003: Bachelor of Medical Science (UNSW) Bachelor of Medicine, Bachelor of Surgery (UNSW) FRACP Part 1 FRACP Part 2 (Endocrinology) FRACP (Clinical Pharmacology – Cardiovascular)

CLINICAL EXPERIENCE 1991: 1992: Intern, Royal Prince Alfred Hospital, Sydney Resident Medical Officer, Prince Henry and Prince of Wales Hospitals, Sydney Psychiatry Registrar, Prince of Wales Hospital and London, UK Psychiatry Registrar, Prince Henry Hospital Medical Registrar, Prince Henry and Prince of Wales Hospitals Medical Registrar, St George Hospital, Sydney Medical Registrar, St George Hospital, Sydney Endocrinology/Diabetes Registrar, St Vincent’s Hospital, Sydney Senior Endocrinology Registrar, St Vincent’s Hospital, Sydney Senior Endocrinology Registrar, Concord Hospital, Sydney; Research Registrar in Clinical Pharmacology, St George Hospital, Sydney Clinical Research Physician/Clinical Pharmacology Registrar, Department of Clinical Pharmacology, St George Hospital, Sydney Locum Staff Specialist, Department of Clinical Pharmacology, St George Hospital, Sydney (part-time) Consultant Endocrinologist in private practice, Sydney Staff Specialist (Clinical Research), Department of Clinical Pharmacology, St George Hospital, Sydney (fractional 0.3) Honorary Medical Officer, Diabetes Centre, St Vincent’s Hospital, Sydney CEO & Principal Investigator, Australian Clinical Research Centre, Sydney Consultant Endocrinologist in private practice Visiting Medical Officer (Endocrinology), and Chairman, Drugs & Therapeutics Committee (from 2007), The Sutherland Hospital, Caringbah Honorary Medical Officer, Diabetes Centre, St Vincent’s Hospital, Sydney Consultant Endocrinologist in private practice CEO & Principal Investigator, Australian Clinical Research Centre, Sydney (see http://acrc.webcoda.net.au/CEOPrincipalInvestigator/tabid/65/Default.aspx for snapshot)

1993: 1994: 1995: 1996: 1997: 1998:

1999: 2000:

2001:

2002–3:

2004–8:

BASIC & CLINICAL RESEARCH EXPERIENCE

1. Department of Neurology, Prince Henry/Prince of Wales Hospitals, Sydney (1988) One year of neuropharmacology research conducted in the Department of Neurology at the Prince Henry Hospital, leading to the award of Bachelor of Medical Science. The work was supervised by Professor J W Lance and investigated the pathways involved in the perception of head pain. Experiments were performed on anaesthetised cats. 2. Metabolism and Obesity Program, Garvan Institute of Medical Research, Sydney (1998) Participation in ongoing research examining the relationship between muscle lipids and insulin resistance in humans. This work has been of major clinical relevance to the pathogenesis of type 2 diabetes mellitus. 3. Department of Clinical Pharmacology, St George Hospital, Sydney (2000) A one-year clinical research project evaluating the effects of cerivastatin (in males) and phytooestrogens (in females) on endothelial function in type 2 diabetes mellitus, in the setting of a doubleblind, randomised, placebo-controlled trial. The studies used forearm blood flow and plethysmographic techniques to measure the haemodynamic responses to various agents in the presence of the above drugs. The work was supervised by Professor L G Howes. 4. Department of Clinical Pharmacology, St George Hospital, Sydney (2000 – 2003) Co-investigator for sponsored clinical trials in areas of hypertension, cardiovascular disease and diabetes (Principal Investigator: Professor Laurie Howes). 5. Australian Clinical Research Centre, Sydney (2002 – 2008) CEO & Principal Investigator for sponsored clinical trials (Phase IIa – IV) in diabetes, endocrinology, cardiovascular medicine (hypertension, dyslipidaemia, atrial fibrillation and CV outcomes trials) and other areas in internal medicine. (A full list of trials performed, recruitment success and sponsors (many of which were GSK) is available on request.)  ICH/GCP training received at numerous Investigator and Site Initiation Meetings since 2000;  Regular liaising with IRB/HRECs* and the TGA;  Signing off AEs/SAEs and experience in drug safety/pharmacovigilance *including the HREC at the Prince of Wales Hospital (SESIAHS – Northern Section) and the Bellberry (private) HREC

EDITORIAL EXPERIENCE 1. Australian Medicines Handbook: Expert reviewer, Endocrine & Metabolic Drugs (2008 – )

COMMERCIAL EXPERIENCE

1. Southern Diabetes & Endocrinology (2001–8)
    Successful private general endocrinology practice set up de novo; Serviced by four individual endocrinologists simultaneously; Well-recognised throughout the local region by general practitioners and patients

2. CEO and Principal Investigator, Australian Clinical Research Centre (ACRC) (2002–8)
Sponsored clinical trials (mainly, but not exclusively, the cardiovascular/metabolic therapeutic areas) were performed under contract to virtually every large pharmaceutical company and CRO (in particular AstraZeneca, Pfizer, MSDA, Novo Nordisk, Eli Lilly and GSK). Employed a team of ten staff in whom a successful team dynamic was fostered under my leadership to enhance team-building and personnel empowerment, as well as conflict management (where appropriate or necessary); Successfully handled budgets, timelines and utilised strategic thinking oriented towards business goals, such that ACRC’s operating profit increased exponentially from 2004 onwards; 2007 fiscal year turnover in excess of $1 million (extrapolated 2008 higher); Sold to Symbion Health Ltd in February 2008

      

3. Southern Densitometry Centre (2004–08)
Running of successful private bone densitometry (BMD) practice with leased Lunar Prodigy™ densitometer; This functioned as o a service to local general practitioners and patients; o a means of conducting osteoporosis trials It was also commercialised for Novartis Pharmaceuticals for the carrying out of a pilot clinical trial for the non-hospital/clinic use of intravenous zoledronic acid for osteoporosis

PUBLICATIONS
1. Lowy A. The pharmacology of the central processing of head pain, BMedSc thesis, University of New South Wales, 1988 2. Boers P, Lowy A, Lambert GA, Angus-Leppan H, Zagami AS. Effect of ergot alkaloids on cervical spinal cord neurons with craniovascular input, Soc Neurosci Abstr 1989;15: 187. 3. Lowy AJ, Lambert GA. Effect of ergot alkaloids on cervical spinal cord processing of nociceptive input from cerebral blood vessels, Neurosci Lett 1989;Supp 34: S109. 4. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids, Brain Research 1992;597: 321-330. 5. Lowy AJ, Sachdev PS, Lindeman R, Wilson AJ. Disseminated intravascular coagulopathy and thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome, Aust NZ J Med 1995;25: 368. 6. Chisholm DJ, Poynten AM, Ellis BA, Furler SM, Lowy AJ, Kraegen EW, Campbell LV, Cooney GJ. Relationship of insulin sensitivity with abdominal fat and muscle long chain acyl CoA’s (LCACs) in men, Diabetologia 1998;41, Supp 1: 801 7. Poynten AM, Ellis, BA, Furler, SM, Lowy AJ, Kraegen EW, Campbell, LV, Cooney GJ, Chisholm DJ. Relationship of muscle long chain acyl CoAs (LCACs) and abdominal fat with insulin sensitivity in men, ADEA/ADS Annual Scientific Meetings, Proceedings, Perth (1998). 8. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 2000;279: E554-E560. 9. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Chisholm DJ, Cooney GJ. Expression of genes involved in lipid metabolism correlate with PPAR- expression in human skeletal muscle. J Clin Endocrinol Metab 2000;85: 4293-4297. 10. Furler SM, Poynten AM, Kriketos AD, Lowy AJ, Ellis BA, Maclean EL, Kraegen EW, Campbell LV, Chisholm DJ. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. Obesity Res 2001;9: 535-43. 11. Lowy AJ, Chisholm DJ. Insulinoma masked by pregnancy, Intern Med J 2001; 31: 128-129. 12. Lowy AJ, Howes, LG. ACE inhibitors and angiotensin receptor blockers in type 2 diabetes (Review). Current Therapeutics 2002; 43: 47-51 13. Lowy AJ, Howes, LG. ACE inhibitors and angiotensin receptor blockers in type 2 diabetes (Review). New Ethicals J 2002; 5: 45-49 14. Howes LG, Lowy A. Selective COX-2 inhibition: cardiovascular consequences (Review). New Ethicals J 2003; 6: 11-16 15. Lowy AJ and Phillips, PJ. Getting to know the glitazones. Medicine Today 2004; 5: 54-65 16. Tran D, Lowy A, Howes JB, Howes LG. The effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes, Obesity and Metabolism 2005; 7:273-281 17. Phillips P, Lowy A. Focus on Avandamet. Medicine Today 2007; 8: 57-59

PROFESSIONAL ORGANISATIONS – MEMBERSHIP

1. Australian Diabetes Society (ADS) 2. Endocrine Society of Australia (ESA) 3. Australian & New Zealand Bone & Mineral Society (ANZBMS) 4. Cardiac Society of Australia & New Zealand (CSANZ) 5. Australian Society of Clinical & Experimental Pharmacologists & Toxicologists (ASCEPT) 6. Australian Association of Pharmaceutical Physicians (APPA – pending) 7. American Association of Clinical Endocrinologists (AACE) 8. The (US) Endocrine Society 9. American Diabetes Association (ADA) 10. European Association for the Study of Diabetes (EASD) 11. Fellow, Royal Australasian College of Physicians 12. Diabetes Australia (NSW) Advisory Group 13. Avant Medical Defence 14. Australian Medical Association

REFEREES

Professor Mark E Cooper Associate Director; Head, JDRF Diabetes and Metabolism Division Baker Heart Research Institute 75 Commercial Road Melbourne VIC 3004 Tel: (03) 8532 1362 Email: mark.cooper@baker.edu.au Professor Donald J Chisholm, AO Emeritus Professor of Endocrinology Garvan Institute of Medical Research 384 Victoria Street Darlinghurst NSW 2010 Tel: (02) 9295 8205 Email: d.chisholm@garvan.org.au Professor Lesley V Campbell, AM Professor of Medicine and Director Diabetes Centre St Vincent’s Hospital 372 Victoria Street Darlinghurst NSW 2010 Tel: (02) 8382 2622 Email: l.campbell@garvan.org.au Professor Richard O Day, AM Professor of Clinical Pharmacology Director of Clinical Pharmacology & Toxicology Executive Director, Clinical Trials Centre St Vincent’s Hospital Darlinghurst NSW 2010 Co-Director, NSW Medicines Information Centre Tel: (02) 8382 2331 Email: r.day@unsw.edu.au Dr John Miller Medical Director Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Email: jomi@novonordisk.com Dr Catharina Dillenbeck Clinical Quality Manager AstraZeneca Pty Ltd Alma Rd North Ryde NSW 2113 Tel: (02) 9978 3659 Email: catharina.dillenbeck@astrazeneca.com